My Treatment Approach: Acute Myeloid Leukemia (AML)

Richard Stone, MD, and Eunice Wang, MD, discuss recent advances in the treatment of newly-diagnosed acute myeloid leukemia and its impact on clinical practice.

EP. 1: Secondary Acute Myeloid Leukemia (AML): Overview

May 26th 2022

Richard Stone, MD, and Eunice Wang, MD, define secondary acute myeloid leukemia treatment goals and how treatment has been affected by the COVID-19 pandemic.

EP. 2: Patient Profile 1: Patient with Secondary Acute Myeloid Leukemia

May 26th 2022

Two experts review a patient profile and discuss whether the patient meets the criteria for secondary acute myeloid leukemia (AML).

EP. 3: CPX-351 in Treatment of AML and Clinical Considerations

June 2nd 2022

Richard Stone, MD, and Eunice Wang, MD, comment on the role of CPX-351 in the treatment of secondary AML and offer practice pointers for treatment with this drug, including management of adverse events.

EP. 4: Selecting the Right Patients for CPX-351 or Venetoclax + Azacitidine in AML

June 2nd 2022

Richard Stone, MD, and Eunice Wang, MD, provide an overview of how patients with AML are selected for treatment with CPX-351 or the combination of venetoclax-azacitidine.

EP. 5: Considerations for Venetoclax + Azacitidine Administration and AE Management

June 9th 2022

Richard Stone, MD, and Eunice Wang, MD, discuss considerations and challenges related to the administration of venetoclax and azacitidine in the community setting, and share strategies for managing adverse events associated with this combination.

EP. 6: Role of MRD in Treatment Decision Making in AML

June 9th 2022

Two experts discuss the clinical implications of minimal residual disease (MRD) and how it has affected treatment for patients with acute myeloid leukemia (AML).

EP. 7: Patient Profile 2: Patient with de novo AML and IDH2 Mutation

June 16th 2022

Drs Richard Stone and Eunice Wang review the clinical profile of a 67-year-old man with newly diagnosed acute myeloid leukemia (AML) and an IDH2 mutation.

EP. 8: Importance of Molecular Testing in Acute Myeloid Leukemia to Guide Treatment

June 16th 2022

Richard Stone, MD, and Eunice Wang, MD, explain how molecular biomarker testing influences their treatment decision-making in patients with acute myeloid leukemia (AML).

EP. 9: Targeted Therapy in Patients with AML and IDH1/IDH2 Mutations

June 23rd 2022

An overview of treatment options in patients who present with IDH1/IDH2 mutations and how to manage treatment-related adverse events.

EP. 10: Unmet Needs and Future Perspectives in AML

June 23rd 2022

Richard Stone, MD, and Eunice Wang, MD, share upcoming treatment advances they look forward to for patients with acute myeloid leukemia (AML).